RECORD // Company

PharmaCyte Biotech, Inc.

Formerly: NUVILEX, INC.; EFOODSAFETY COM INC

Built 2026-11-22T03:49:29Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-07-31, filed 2026-09-14 · accession 0001683168-26-007106

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-07-3110-Q2026-09-140001683168-26-0071062026-11-22 03:49 UTCReport an error
Net income (loss)$-5,081,1913 months ended 2026-07-3110-Q2026-09-140001683168-26-0071062026-11-22 03:49 UTCReport an error
Cash and cash equivalents$17,738,991at 2026-07-3110-Q2026-09-140001683168-26-0071062026-11-22 03:49 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001157075
Ticker
PMCB
EIN
621772151
CUSIP
62856X300
Record ID
sx:sec:0001157075

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
State of incorporationNV2026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
Fiscal year end (MMDD)04302026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
Business address3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS, NV, 891692026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 03:49 UTCReport an error
Revenue (fiscal year ended 2026-04-30)$02026-04-3010-K, XBRL Revenues2026-11-22 03:49 UTCReport an error
Net income (loss) (fiscal year ended 2026-04-30)$-19,424,6542026-04-3010-K, XBRL NetIncomeLoss2026-11-22 03:49 UTCReport an error
Total assets (at 2026-04-30)$46,753,2422026-04-3010-K, XBRL Assets2026-11-22 03:49 UTCReport an error
Stockholders' equity (at 2026-04-30)$33,294,9262026-04-3010-K, XBRL StockholdersEquity2026-11-22 03:49 UTCReport an error
Cash and cash equivalents (at 2026-04-30)$18,603,8992026-04-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 03:49 UTCReport an error
Operating cash flow (fiscal year ended 2026-04-30)$-5,152,9142026-04-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:49 UTCReport an error
Form D total offering amount (D filed 2025-09-04)$7,000,0002025-09-04D2026-11-22 03:49 UTCReport an error
Form D total amount sold (D filed 2025-09-04)$7,000,0002025-09-04D2026-11-22 03:49 UTCReport an error
Form D industry groupBiotechnology2025-09-04D2026-11-22 03:49 UTCReport an error
Form D revenue rangeDecline to Disclose2025-09-04D2026-11-22 03:49 UTCReport an error
Form D date of first sale2025-08-172025-09-04D2026-11-22 03:49 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-11-19)Agreement. Consent and Warrant Exchange Agreement On November 15, 2026, PharmaCyte Biotech, Inc. (the “Company”) entered into a Consent and Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with Q/C Technologies, Inc., formerly known as TNF Pharmaceuticals, Inc. (“Q/C”). Under the Warrant Exchange Agreement, the Company agreed to exchange 851,304 Series G Long-Term Warrants to purchase shares of Q/C’s common stock, par value $0.001 per share (the “Q/C Common Stock”), held by the Company, which were issued pursuant to that certain Securities Purchase Agreement, dated May 20, 2024, by and among Q/C and the purchasers party thereto, including the Company (such exchanged warrants…2026-11-19SEC EDGAR 8-K 0001683168-26-008964 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
8-K Item 2.01, Completion of Acquisition or Disposition (filed 2026-11-19)of Assets. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.2026-11-19SEC EDGAR 8-K 0001683168-26-008964 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security (filed 2026-11-13)Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.2026-11-13SEC EDGAR 8-K 0001683168-26-008705 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation (filed 2026-11-13)or Bylaws; Change in Fiscal Year. On November 10, 2026, PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a certificate of amendment (the “Certificate of Amendment”) to its Articles of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-19 (the “Reverse Stock Split”), with an effective date of November 12, 2026. The Reverse Stock Split was approved by the Company’s stockholders at the Company’s annual meeting of stockholders held on March 30, 2026, which authorized the Company’s board of directors to effect a…2026-11-13SEC EDGAR 8-K 0001683168-26-008705 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-13)On November 11, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.2026-11-13SEC EDGAR 8-K 0001683168-26-008705 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
8-K Item 4.01, Changes in Registrant’s Certifying Accountant (filed 2026-10-16)(a) Dismissal of Independent Registered Public Accounting Firm On October 14, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of PharmaCyte Biotech, Inc. (the “Company”) dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm, effective as of that date. The reports of CBIZ CPAs on the Company’s consolidated financial statements as of and for the fiscal years ended April 30, 2026 and April 30, 2025 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal years ended April 30, 2026 and April 30, 2025, and…2026-10-16SEC EDGAR 8-K 0001683168-26-007934 (text as filed, excerpt)2026-11-22 03:49 UTCReport an error
Largest institutional holder #1 (13F as filed): Quinn Opportunity Partners LLC$479,7942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$448,6212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #3 (13F as filed): JANE STREET GROUP, LLC$340,2402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #4 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$275,6592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #5 (13F as filed): UBS Group AG$229,6862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #6 (13F as filed): Balyasny Asset Management L.P.$224,9992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #7 (13F as filed): ADAR1 Capital Management, LLC$195,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD FIDUCIARY TRUST CO$167,9072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #9 (13F as filed): STATE STREET CORP$98,6902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error
Largest institutional holder #10 (13F as filed): DIMENSIONAL FUND ADVISORS LP$74,3262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:49 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.